List view / Grid view
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
Tom Darlington, Senior Director at nanoComposix, discusses scaling up manufacturing of nanomaterials for regulated applications and the rewards of working on biomedical projects.
Drug Target Review connects with Dr Stefan Braam, co-founder and CTO of Cellistic, and Andy Holt, CCO of Cellistic, for a rundown on today’s landscape for allogeneic cell therapies.
As new variants of the SARS-CoV-2 virus emerge, leading scientists Dr Oscar Bastidas and Dr Zoran Sevarac explore how their latest research identified a structured frequency domain profile in data with no discernible pattern. Their article also emphasises that it remains imperative to continue learning about this pathogen’s molecular machinery…
Matthew Lloyd from the University of Bath reveals the importance of the Z-factor and Z’-factor in high-throughput screening, and how they can be used to determine assay performance, perform quality control on the screen, and identify active compounds.
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.
Sheraz Gul, Head of Assay Development and Drug Repurposing at the Fraunhofer Institute, discusses the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research to decrease the risk of potentially undesirable events in later clinical studies.
Learn more about the CellCelector platform and its unique nanowell plate technology, which is key to the high cell integrity and outgrowth rates after picking.
Transform your drug manufacturing process with the latest breakthroughs in technology. Effortlessly identify and differentiate degradation components of PS20 in protein-containing samples.
In this article, Drug Target Review's Ria Kakkad and Izzy Wood explore the results of the latest research on lab automation techniques and technologies designed to accelerate drug discovery.
Download your FREE ebook on assays, featuring articles from experts who write about developments in screening and the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research.
